Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 31 peer-reviewed journal articles Updated
Pediatric Pulmonology · Genetic Surfactant Dysfunction

The Major Genes: SFTPB, SFTPC, ABCA3, and NKX2-1

At a Glance

Genetic surfactant disorders result from changes in genes that make, transport, or regulate lung surfactant. The specific gene—SFTPB, SFTPC, ABCA3, or NKX2-1—helps explain whether disease starts at birth or later, how severe it may be, how it is inherited, and whether the brain or thyroid may also be affected.

Genetic surfactant dysfunction is not a single disease, but a group of distinct conditions caused by variants in different genes. Each gene acts as a unique instruction manual for building, transporting, or regulating the surfactant system [1]. When one of these manuals is altered, the lungs cannot function properly, but the way they break—and how severely they are affected—depends on which gene is involved [2].

Key Genetic Terms to Know:

  • Autosomal Recessive: The child must inherit two altered copies of the gene (one from each parent) to have the disease.
  • Autosomal Dominant: Only one altered copy of the gene is needed to cause the disease.
  • Pathogenic / Likely Pathogenic: A genetic variant that is known or highly suspected to cause disease.
  • Variant of Uncertain Significance (VUS): A genetic change whose impact on health is not yet fully understood.

SFTPB: The Critical Missing Piece

The SFTPB gene provides instructions for making Surfactant Protein B (SP-B). This protein is absolutely essential for surfactant to spread across the air sacs and lower surface tension [1].

  • The Problem: Most variants in this gene are loss-of-function, meaning the body makes little to no working SP-B [3].
  • The Result: Without SP-B, the surfactant system fails. This typically causes severe, life-threatening respiratory failure immediately at birth [4].
  • Inheritance: Autosomal recessive. A baby must inherit two altered copies (one from each parent) to have the disease. Parents are usually “carriers” with no symptoms [5].

ABCA3: The Broken Transporter

The ABCA3 gene is the most common cause of genetic surfactant dysfunction [6]. This gene transports the fats (lipids) needed to build surfactant into storage units called lamellar bodies [7][8].

  • The Problem: Variants can stop the protein from being made entirely (null variants), or stop it from moving lipids correctly [9][10].
  • The Result: Because there are hundreds of different ABCA3 variants, severity varies widely [8]. Classic ABCA3 disease occurs when a baby has two severe “null” variants, often leading to severe lung failure at birth [11]. If the variants are less severe, the baby may have Childhood Interstitial Lung Disease (chILD), which develops more slowly [12][13].
  • Inheritance: Usually autosomal recessive (requires two variants, or biallelic mutations). If only a single (monoallelic) variant is found, it usually means the person is a carrier. However, its significance can sometimes be uncertain and must be interpreted carefully by a clinical geneticist [14][15].

SFTPC: The Misfolded Protein

The SFTPC gene makes Surfactant Protein C (SP-C).

  • The Problem: These variants cause the SP-C protein to misfold or get stuck inside the lung cells [16]. This creates cellular stress, eventually damaging the cells that are supposed to keep the lungs healthy [17].
  • The Result: This condition is highly unpredictable. It can cause severe disease in newborns, but it more commonly appears later in infancy, childhood, or even adulthood as pulmonary fibrosis [18][19].
  • Inheritance: Autosomal dominant. A baby only needs one altered copy of the gene to be affected [20]. It can be inherited from a parent with mild symptoms, or it can be a de novo mutation (a new change that started with the baby) [1].

NKX2-1: The “Master Switch”

NKX2-1 acts like a master switch that turns on other genes in the lungs, brain, and thyroid during development [21][22].

  • The Problem: Variants reduce the amount of this switch available, leading to Brain-Lung-Thyroid Syndrome [23][24].
  • The Result: Affected children may have issues in one, two, or all three areas [25]:
    • Lungs: Respiratory distress at birth or chronic lung disease [22].
    • Brain: Involuntary movements (chorea) or low muscle tone (hypotonia) [24].
    • Thyroid: An underactive thyroid gland (hypothyroidism) [22].
  • Inheritance: Autosomal dominant. It can be inherited or occur for the first time in the baby [26][27].

Other Related Genes

The four genes above are important examples, but they are not the only causes of childhood interstitial lung disease (chILD). Testing may also look for genes like CSF2RA/CSF2RB, FOXF1, or TBX4. Variants in SFTPA1 and SFTPA2 can also cause lung disease, typically leading to lung scarring (fibrosis) later in life [28][29]. In some families, specific SFTPA1/A2 variants carry an increased risk of lung cancer in adulthood, but this risk is highly specific to the family and variant, and requires specialist genetic counseling [30][31].

Common questions in this guide

What are the major genes linked to genetic surfactant dysfunction?
The major genes discussed are SFTPB, SFTPC, ABCA3, and NKX2-1. Other genes, including CSF2RA, CSF2RB, FOXF1, TBX4, SFTPA1, and SFTPA2, can also contribute to childhood interstitial lung disease or later lung scarring.
What does an SFTPB variant mean for a newborn?
Disease-causing SFTPB variants usually reduce or eliminate functional surfactant protein B. When a baby has altered copies of the gene from both parents, the condition commonly causes severe, life-threatening breathing failure soon after birth; each parent is often an unaffected carrier.
Why can ABCA3-related lung disease vary so much?
ABCA3 helps move the fats needed to make surfactant into lung storage structures. Babies with two severe variants that eliminate the protein may develop lung failure at birth, while less severe variants may cause slower childhood interstitial lung disease; one variant alone usually indicates carrier status but needs expert interpretation.
How is SFTPC-related disease inherited, and when can it appear?
SFTPC disease is usually autosomal dominant, so one altered copy can be enough to cause disease. Symptoms may begin in the newborn period, childhood, or adulthood, and later disease can include pulmonary fibrosis; the variant may be inherited or arise for the first time in the child.
What health problems are linked to an NKX2-1 variant?
NKX2-1 variants can cause Brain-Lung-Thyroid Syndrome. A child may have respiratory distress or chronic lung disease, involuntary movements or low muscle tone, an underactive thyroid, or a combination of these problems, so care may include monitoring all three areas.
What do biallelic, monoallelic, and VUS mean on a genetic report?
Biallelic means that altered copies were identified in both copies of a gene, while monoallelic means that a change was found in only one copy. A variant of uncertain significance, or VUS, is a genetic change whose health effect is not yet clear, so its meaning must be reviewed with a clinical geneticist.
Should parents and siblings have genetic testing?
Testing parents and other relatives may show who carries a familial variant and whether a child or sibling could be at risk. A clinical geneticist or genetic counselor can recommend which relatives should be tested and explain what the results may mean for future pregnancies.

Get notified when new evidence is published on Chronic respiratory distress with surfactant metabolism deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (31)
  1. 1

    Genetic Disorders of Surfactant Metabolism.

    Nevel RJ, Brennan SK, Wambach JA

    NeoReviews 2025; (26(5)):e328-e338 doi:10.1542/neo.26-5-014.

    PMID: 40306683
  2. 2

    THERAPIES FOR NEONATAL DISEASES OF THE SURFACTANT SYSTEM.

    McCray PB

    Transactions of the American Clinical and Climatological Association 2025; (135()):119-129.

    PMID: 40771632
  3. 3

    Surfactant protein B deficiency: the RespiRare cohort.

    Fleury M, Delestrain C, Roditis L, et al.

    Thorax 2025; (80(2)):109-112 doi:10.1136/thorax-2024-221947.

    PMID: 39632082
  4. 4

    Gene Therapy Potential for Genetic Disorders of Surfactant Dysfunction.

    Cooney AL, Wambach JA, Sinn PL, McCray PB

    Frontiers in genome editing 2021; (3()):785829 doi:10.3389/fgeed.2021.785829.

    PMID: 35098209
  5. 5

    Congenital surfactant protein B (SP-B) deficiency: a case report.

    Khalsi F, Chaabene M, Romdhane MB, et al.

    The Pan African medical journal 2023; (44()):158 doi:10.11604/pamj.2023.44.158.35316.

    PMID: 37455866
  6. 6

    Inherited pulmonary surfactant metabolism disorders in Argentina: Differences between patients with SFTPC and ABCA3 variants.

    Balinotti JE, Mallie C, Maffey A, et al.

    Pediatric pulmonology 2023; (58(2)):540-549 doi:10.1002/ppul.26225.

    PMID: 36324278
  7. 7

    Lentiviral-mediated gene complementation to rescue pathogenic ABCA3 variants.

    Cooney AL, Lamer S, Yang P, et al.

    American journal of respiratory cell and molecular biology 2026; (74(8)):1089-1102 doi:10.1093/ajrcmb/aanag043.

    PMID: 42089300
  8. 8

    Lung disease caused by ABCA3 mutations.

    Kröner C, Wittmann T, Reu S, et al.

    Thorax 2017; (72(3)):213-220 doi:10.1136/thoraxjnl-2016-208649.

    PMID: 27516224
  9. 9

    ABCA3 missense mutations causing surfactant dysfunction disorders have distinct cellular phenotypes.

    Schindlbeck U, Wittmann T, Höppner S, et al.

    Human mutation 2018; (39(6)):841-850 doi:10.1002/humu.23416.

    PMID: 29505158
  10. 10

    Biologic characterization of ABCA3 variants in lung tissue from infants and children with ABCA3 deficiency.

    Xu KK, Wegner DJ, Geurts LC, et al.

    Pediatric pulmonology 2022; (57(5)):1325-1330 doi:10.1002/ppul.25862.

    PMID: 35170262
  11. 11

    Phenotype-Genotype Correlations in ABCA3 Patients-The RespiRare Cohort.

    Fleury M, Delestrain C, Hadchouel A, et al.

    Pediatric pulmonology 2025; (60(10)):e71324 doi:10.1002/ppul.71324.

    PMID: 41090249
  12. 12

    ABCA3, a key player in neonatal respiratory transition and genetic disorders of the surfactant system.

    Peca D, Cutrera R, Masotti A, et al.

    Biochemical Society transactions 2015; (43(5)):913-9 doi:10.1042/BST20150100.

    PMID: 26517903
  13. 13

    ABCA3-related interstitial lung disease beyond infancy.

    Li Y, Seidl E, Knoflach K, et al.

    Thorax 2023; (78(6)):587-595 doi:10.1136/thorax-2022-219434.

    PMID: 36808083
  14. 14

    Respiratory Outcomes in Children With Neonatal Respiratory Distress Syndrome and Monoallelic ABCA3 Variants.

    Ramírez VO, Wambach JA, Nevel RJ, et al.

    Pediatric pulmonology 2026; (61(6)):e71695 doi:10.1002/ppul.71695.

    PMID: 42295024
  15. 15

    Increased Risk of Interstitial Lung Disease in Children with a Single R288K Variant of ABCA3.

    Wittmann T, Frixel S, Höppner S, et al.

    Molecular medicine (Cambridge, Mass.) 2016; (22()):183-191 doi:10.2119/molmed.2015.00244.

    PMID: 26928390
  16. 16

    An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis.

    Katzen J, Wagner BD, Venosa A, et al.

    JCI insight 2019; (4(6)).

    PMID: 30721158
  17. 17

    Novel insights into surfactant protein C trafficking revealed through the study of a pathogenic mutant.

    Dickens JA, Rutherford EN, Abreu S, et al.

    The European respiratory journal 2022; (59(1)) doi:10.1183/13993003.00267-2021.

    PMID: 34049951
  18. 18

    A rare interstitial lung disease in young adulthood due to surfactant protein C gene mutation: Two case reports with brief literature review.

    Sengul Y, Gosche E, Hazelton T

    Radiology case reports 2025; (20(9)):4299-4303 doi:10.1016/j.radcr.2025.05.051.

    PMID: 40575365
  19. 19

    Towards personalized therapies for genetic disorders of surfactant dysfunction.

    Peers de Nieuwburgh M, Wambach JA, Griese M, Danhaive O

    Seminars in fetal & neonatal medicine 2023; (28(6)):101500 doi:10.1016/j.siny.2023.101500.

    PMID: 38036307
  20. 20

    Surfactant Protein C Deficiency in a Puerto Rican Adolescent With a Rare SFTPC Genetic Variant.

    Acosta-Rivera V, Melendez-Montañez JM, Diaz-Sotomayor F, De Jesús-Rojas W

    Cureus 2021; (13(8)):e17422 doi:10.7759/cureus.17422.

    PMID: 34589332
  21. 21

    A Novel Mutation in NKX2-1 Shows Dominant-Negative Effects Only in the Presence of PAX8.

    Shinohara H, Takagi M, Ito K, et al.

    Thyroid : official journal of the American Thyroid Association 2018; (28(8)):1071-1073 doi:10.1089/thy.2017.0481.

    PMID: 29882472
  22. 22

    Systematic review of thyroid function in NKX2-1-related disorders: Screening and diagnosis.

    Carmona-Hidalgo B, Martín-Gómez C, Herrera-Ramos E, et al.

    PloS one 2024; (19(7)):e0303880 doi:10.1371/journal.pone.0303880.

    PMID: 38990976
  23. 23

    Functional characterization of two novel NKX2-1 frameshift variants that cause pulmonary surfactant dysfunction.

    Wang H, Jiang G, Dai D, et al.

    Pediatric research 2024; (95(3)):744-751 doi:10.1038/s41390-023-02882-x.

    PMID: 37935886
  24. 24

    International Registry of NKX2-1-Related Disorders: Clinical, Genetic, and Imaging Perspectives.

    Nou-Fontanet L, Ravelli C, Burglen L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2026; (41(4)):889-900 doi:10.1002/mds.70187.

    PMID: 41552915
  25. 25

    Respiratory and other organ manifestations in NKX2-1-related disorders: a systematic review.

    Michel K, Ruiz-Ramos A, Nou-Fontanet L, et al.

    Frontiers in medicine 2025; (12()):1507513 doi:10.3389/fmed.2025.1507513.

    PMID: 40395234
  26. 26

    Differential diagnosis of Huntington's disease- neurological aspects of NKX2-1-related disorders.

    Skwara J, Nowicki M, Sharif L, et al.

    Journal of neural transmission (Vienna, Austria : 1996) 2024; (131(9)):1013-1024 doi:10.1007/s00702-024-02800-3.

    PMID: 38916623
  27. 27

    Identical deletion at 14q13.3 including PAX9 and NKX2-1 in siblings from mosaicism of unaffected parent.

    Hayashi S, Yagi M, Morisaki I, Inazawa J

    Journal of human genetics 2015; (60(4)):203-6 doi:10.1038/jhg.2014.123.

    PMID: 25608831
  28. 28

    A novel germline mutation of the SFTPA1 gene in familial interstitial pneumonia.

    Doubková M, Staňo Kozubík K, Radová L, et al.

    Human genome variation 2019; (6()):12 doi:10.1038/s41439-019-0044-z.

    PMID: 30854216
  29. 29

    Lung cancer is also a hereditary disease.

    Benusiglio PR, Fallet V, Sanchis-Borja M, et al.

    European respiratory review : an official journal of the European Respiratory Society 2021; (30(162)) doi:10.1183/16000617.0045-2021.

    PMID: 34670806
  30. 30

    Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer.

    Legendre M, Butt A, Borie R, et al.

    The European respiratory journal 2020; (56(6)) doi:10.1183/13993003.02806-2020.

    PMID: 32855221
  31. 31

    Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer.

    Nathan N, Giraud V, Picard C, et al.

    Human molecular genetics 2016; (25(8)):1457-67 doi:10.1093/hmg/ddw014.

    PMID: 26792177

This page explains how SFTPB, SFTPC, ABCA3, and NKX2-1 variants can affect lung health for educational purposes and does not replace medical advice. A pediatric pulmonologist and clinical geneticist should interpret your child’s results and guide care.

Guide contents Chronic respiratory distress with surfactant metabolism deficiency
Research & Literature
01 Building a Foundation 03 Finding Answers